

Erdafitinib

A First-In-Class Agent for Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma and Fibroblast Growth Factor Receptor (FGFR) Alterations

Waleed Shalaby, MD, PhD
Medical Director, Oncology Medical Affairs


Agenda

- Bladder Cancer Key Statistics
- Treatment Landscape
- FGFR Alterations in Solid Tumors
- Mechanism of Action of Erdafitinib
- Review of Clinical Data
- Conclusions
- Questions

Bladder Cancer: Key Statistics

- Estimates for 2018
 - New cases: 81,190
 - Deaths: 17,240
- Demographics
 - Median Age: 72
 - 75% Male (*3rd most common cancer in men*)
 - 25% Female (*11th most common cancer in women*)
- Presentation
 - 10–15% are estimated to present with metastasis
 - 80-90% painless gross hematuria
 - 20-30% irritative bladder
- 5-Year Survival
 - Stage I: 88%
 - Stage II: 63%
 - Stage III: 46%
 - Stage IV: 15%
- Risk of Progression
 - Grade I: 2-4%
 - Grade II: 5-7%
 - Grade III: 33-64%

Treatment Landscape



Systemic Therapy for Recurrent or Metastatic Disease

- Platinum doublets have been the preferred 1L treatment advanced UC
- A substantial portion of patients (~40-50%) cannot receive cisplatin due to renal impairment or other comorbidities; for these patients, gemcitabine + carboplatin is preferred
- Five PD-(L)1 agents are approved for 2L treatment after progression on platinum-based chemo. Pembrolizumab has become preferred 2L SOC.

Treatment Options for Metastatic or Recurrent Bladder Cancer

■ L1 Platinum-Based Chemotherapy

- Gemcitabine/Cisplatin or MVAC
 - Median OS: 13.8 months
 - Median Time to Progression: 7.4 months
- Gemcitabine/Carboplatin (*Cisplatin-Ineligible*)
 - Median OS: 9.3 months
 - Median PFS: 5.8 months

■ L2 Single Chemotherapy

- Taxanes (Paclitaxel, Docetaxel Nab-Paclitaxel), Gemcitabine, Premetrexed, Ifosfamide
 - Median OS: ~9 months
 - ORR: ~10-12%

■ L1 Cisplatin-Ineligible Immunotherapy

- Pembrolizumab (PD-1Ab)
 - Median OS: 11.5 months
 - ORR (all subjects): 28.9%
- Atezolizumab (PD-L1 Ab)
 - Median OS: 11.4 months
 - Median PFS: 2.1 months
 - ORR (all subjects): 23.5%

■ L2 Immunotherapy


- Pembrolizumab
 - Median OS: 10.3 months
 - Median PFS: 2.1 months
 - ORR: 21.1%
- Atezolizumab
 - ORR: 14.8%
- Avelumab (PD-L1 Ab)
 - ORR: 17%

Abbreviations: L1- Line 1 or front line; L-2:Line 2 or second line; OS-overall survival; PFS-progression free interval; ORR-overall response rate; MVAC-Methotrexate, Vinblastine, Doxorubicin, Cisplatin

Aberrant FGFR Signaling Plays a Critical Role in Cancer

- Common FGFR alterations leading to pathway activation in cancer subtypes include gene amplifications, chromosomal translocations, and mutations¹
- FGFR3* is commonly altered in bladder cancer, and these alterations result in constitutive *FGFR3* activation²

Frequency and Distribution of FGFR Aberrations Among Cancer Subtypes^{3,4}



- Turner N, Grose R. *Nat Rev Cancer*. 2010;10:116-129.
- Haugsten EM, et al. *Mol Cancer Res*. 2010;8:1439-1452.
- Helsten, et al. *Clin Cancer Res*. 2016;22:259-267.
- Touat, et al. *Clin Cancer Res*. 2015;21:2684-2694

FGFR Alterations Are Common in Cancer

Cancer type	Frequency of <i>FGFR</i> alterations ¹
Metastatic UC	15-20%
NMIBC	40-70%
Cholangiocarcinoma	14-22%
NSCLC	4%
Hepatocellular carcinoma (FGF19 amp by FISH)	21%
Glioblastoma	23%
Breast cancer	3-5%
Ovarian cancer	7%
Head and neck cancer	9-17%

FGFR3 mutations are particularly common (37%) in upper tract UC.²


Abbreviations: *FGFR*, fibroblast growth factor receptor gene; FISH, fluorescence in situ hybridization; NMIBC, non-muscle-invasive bladder cancer; NSCLC, non-small cell lung cancer; UC, urothelial carcinoma

1. TCGA and Genie genomic alteration databases (July 2017).
2. Li Q, et al. *Curr Urol Rep*. 2016;17:12.

Erdafitinib Is a Potent pan-FGFR Inhibitor

- Erdafitinib is an oral pan-FGFR (1-4) inhibitor with IC_{50}^* in the single-digit nanomolar range¹
- Erdafitinib has demonstrated promising activity in patients with metastatic or unresectable UC and other histologies (eg, cholangiocarcinoma) with *FGFR* alterations²⁻⁵

Erdafitinib Structure



Molecular Weight : 446.555 g/mol

* IC_{50} , drug concentration at which 50% of target enzyme activity is inhibited

1. Perera TPS, et al. *Mol Cancer Ther.* 2017;16:1010-1020.
2. Tabernero J, et al. *J Clin Oncol.* 2015;33:3401-3408.
3. Soria J-C, et al. ESMO 2016. Abstract 781PD.


4. Loriot Y, et al. ASCO GU 2018. Abstract 411.
5. Siefker-Radtke A, et al. ASCO GU 2018. Abstract 450.

First Results From the Primary Analysis Population of the Phase 2 Study of Erdafitinib (JNJ-42756493) in Patients With Metastatic or Surgically Unresectable Urothelial Carcinoma and *FGFR* Alterations

Arlene O. Siefker-Radtke,¹ Andrea Necchi,² Se Hoon Park,³ Jesus Garcia-Donas,⁴ Robert A. Huddart,⁵ Earle F. Burgess,⁶ Mark T. Fleming,⁷ Arash Rezazadeh,⁸ Begoña Mellado,⁹ Sergey Varlamov,¹⁰ Monika Joshi,¹¹ Ignacio Duran,¹² Scott T. Tagawa,¹³ Anne O'Hagan,¹⁴ Anjali N. Avadhani,¹⁴ Bob Zhong,¹⁴ Peter De Porre,¹⁵ and Yohann Loriot¹⁶
on behalf of the BLC2001 Study Group sponsored by Janssen Research & Development

¹The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; ²Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ³Samsung Medical Center, Seoul, Korea; ⁴Clara Campal Comprehensive Cancer Center, Madrid, Spain; ⁵Institute of Cancer Research, Sutton, London, UK; ⁶Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, USA; ⁷Virginia Oncology Associates, US Oncology Research, Norfolk, Virginia, USA; ⁸Norton Healthcare, Louisville, Kentucky, USA; ⁹Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; ¹⁰Altai Regional Cancer Center, Barnaul, Russia; ¹¹Penn State Cancer Institute, Hershey, Pennsylvania, USA; ¹²Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain; ¹³Weill Cornell Medical College, New York, NY, USA; ¹⁴Janssen Research & Development, Spring House, Pennsylvania, USA; ¹⁵Janssen Research & Development, Beerse, Belgium; ¹⁶Institut Gustave Roussy, Villejuif, France

Phase 2 BLC2001 Study Design



Primary end point

ORR

Secondary end points

PFS, DoR, OS, safety, predictive biomarker evaluation, and PK

Patients

- Progression on ≥ 1 line prior systemic chemo or within 12 months of (neo)adjuvant chemo
OR
- Chemo-naïve: cisplatin ineligible per protocol criteria^b
- Prior immunotherapy was allowed

Primary hypothesis:

- ORR in Regimen 3 is $> 25\%$
- One-sided $\alpha = 0.025$
- 85% power

^aDose uptitration if ≥ 5.5 mg/dL target serum phosphate not reached by Day 14 and if no TRAEs.

^bIneligibility for cisplatin: impaired renal function or peripheral neuropathy.

Abbreviations: DoR, duration of response; PD, pharmacodynamics; PFS, progression-free survival; PK, pharmacokinetics; QD, daily; TRAEs, treatment-related adverse events.

BLC-2001 Met Primary Objective

		[95% CI]
Patients, n	99	
Response per investigator assessment ^{a,b} , n (%)		
ORR	40 (40.4)	[30.7-50.1]
Complete response	3 (3.0)	
Partial response	37 (37.4)	
Stable disease	39 (39.4)	
Progressive disease	18 (18.2)	
Median time to response	1.4 months	
Median duration of response	5.6 months	[4.2-7.2]
ORR among patient subgroups, n (%)		
Chemo-naïve vs progressed/relapsed after chemo	5/12 (41.7) vs 35/87 (40.2)	
With vs without visceral metastases	30/78 (38.5) vs 10/21 (47.6)	


^aConfirmed with second scan at least 6 weeks following the initial observation of response.

^bResponse in 2 patients was unknown.


21.2% of patients remained on study treatment after 11 months of follow-up

Secondary Endpoints: PFS and OS

Median PFS



Median OS



Exploratory Analysis: *FGFR* Alterations May Select for Patients With UC Unlikely to Respond to PD-(L1) Inhibitors

Patients treated with prior immuno-oncology agent (IO), n

Patients with response (per investigator) to prior IO, n (%)

8 mg continuous dose (n=99)

22

1/22 (5) *

The ORR to erdafitinib was 59% in patients with prior IO treatment

*Patient had been previously treated with PDL-1 inhibitor (progressive disease) and PDL-1 inhibitor combination (complete response).

IO, immunotherapy.

Siefker-Radtke AO, et al. ASCO 2018. Oral presentation. Abstract 4503.

Most Common TRAEs and AEs of Special Interest

	8 mg Continuous Dose (n=99)	
AEs Reported in >20% of Patients, n (%)	Any Grade	Grade \geq 3
Hyperphosphatemia	72 (73)	2 (2)
Stomatitis	54 (55)	9 (9)
Dry mouth	43 (43)	0
Diarrhea	37 (37)	4 (4)
Dysgeusia	35 (35)	1 (1)
Dry skin	32 (32)	0
Alopecia	27 (27)	0
Decreased appetite	25 (25)	0
Hand-foot syndrome	22 (22)	5 (5)
Fatigue	21 (21)	2 (2)
AEs of Special Interest, n (%)		
Hyperphosphatemia	76 (77)	2 (2)
Dry skin	32 (32)	0 (0)
Hand-foot syndrome	23 (23)	5 (5)
Onycholysis	18 (18)	2 (2)
Paronychia	17 (17)	3 (3)
Nail dystrophy	16 (16)	6 (6)
Central serous retinopathy (CSR)	23 (23)	3 (3)
Non-CSR ocular events*	54 (55)	6 (6)

*Most common non-CSR ocular events included dry eye (19%), blurry vision (17%), conjunctivitis (13%) and increased lacrimation (11%).

- Majority of AEs were Grade 1/2, no Grade 4 or 5 TRAEs were reported
- Serious TRAEs were reported in 9 patients (9%)
- Seven patients discontinued erdafitinib due to AEs of special interest. CSR led to discontinuation in three of the seven patients, and no patient had retinal vein or artery occlusion

Abbreviations: TRAE- treatment related adverse events; AE- adverse events

Conclusions

- Urothelial cancer is a significant disease among Medicare patients.
- Some Medicare enrollees will likely need Erdafitinib as inpatients
- Erdafitinib may provide significant clinical improvement
- On the basis of these results, the FDA has granted erdafitinib Breakthrough Therapy Designation status (March 2018)
- Anticipated approval date of Q1 2019

Questions